Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry

  • Marrugal, Ángela
  • Ferrer, Irene
  • Pastor, Maria Dolores
  • Ojeda, Laura
  • Quintanal-Villalonga, Alvaro
  • Carnero, Amancio
  • Molina-Pinelo, Sonia
  • Paz Ares, Luis Gonzaga
Heat shock protein 90 (HSP90) is an important chaperone in lung adenocarcinoma, with relevant protein drivers such as EGFR (epidermal growth factor receptor) and EML4-ALK (echinoderm microtubule-associated protein-like protein4 fused to anaplastic lymphoma kinase) depending on it for their correct function, therefore HSP90 inhibitors show promise as potential treatments for lung adenocarcinoma. To study responses to its inhibition, HSP90 was pharmacologically interrupted by geldanamycin and resorcinol derivatives or with combined inhibition of HSP90 plus HSP70 in lung adenocarcinoma cell lines. Two-dimensional electrophoresis was performed to identify proteomic profiles associated with inhibition which will help to understand the biological basis for the responses. HSP90 inhibition resulted in altered protein profiles that differed according the treatment condition studied. Results revealed 254 differentially expressed proteins after treatments, among which, eukaryotic translation initiation factor3 subunit I (eIF3i) and citrate synthase demonstrated their potential role as response biomarkers. The differentially expressed proteins also enabled signalling pathways involved in responses to be identified; these included apoptosis, serine-glycine biosynthesis and tricarboxylic acid cycle. The proteomic profiles identified here contribute to an improved understanding of HSP90 inhibition and open possibilities for the detection of potential response biomarkers which will be essential to maximize treatment efficacy in lung adenocarcinoma.
Repisalud
Publicación Artículo científico (JournalArticle)

MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma

  • Ferrer, Irene
  • Quintanal-Villalonga, Alvaro
  • Molina-Pinelo, Sonia
  • Garcia-Heredia, Jose Manuel
  • Perez, Marco
  • Suárez, Rocío
  • Ponce-Aix, Santiago
  • Paz Ares , Luis Gonzaga
  • Carnero, Amancio
BACKGROUND: The high incidence and mortality of lung tumours is a major health problem. Therefore, the identification both of biomarkers predicting efficacy for therapies in use and of novel efficacious therapeutic agents is crucial to increase patient survival. MAP17 (PDZK1IP1) is a small membrane-bound protein whose upregulation is reported as a common feature in tumours from diverse histological origins. Furthermore, MAP17 is correlated with tumour progression. METHODS: We assessed the expression of MAP17 in preclinical models, including cell lines and patient-derived xenografts (PDXs), assessing its correlation with sensitivity to different standard-of-care drugs in lung adenocarcinoma, as well as novel drugs. At the clinical level, we subsequently correlated MAP17 expression in human tumours with patient response to these therapies. RESULTS: We show that MAP17 expression is induced during lung tumourigenesis, particularly in lung adenocarcinomas, and provide in vitro and in vivo evidence that MAP17 levels predict sensitivity to therapies currently under clinical use in adenocarcinoma tumours, including cisplatin, carboplatin and EGFR inhibitors. In addition, we show that MAP17 expression predicts proteasome inhibitor efficacy in this context and that bortezomib, an FDA-approved drug, may be a novel therapeutic approach for MAP17-overexpressing lung adenocarcinomas. CONCLUSIONS: Our results indicate a potential prognostic role for MAP17 in lung tumours, with particular relevance in lung adenocarcinomas, and highlight the predictive pot0065ntial of this membrane-associated protein for platinum-based therapy and EGFR inhibitor efficacy. Furthermore, we propose bortezomib treatment as a novel and efficacious therapy for lung adenocarcinomas exhibiting high MAP17 expression.
Repositori Institucional UIB
Publicación Artículo científico (JournalArticle)

The MultiModal Imitation Task: A Validation Study

  • Pronina, Mariia
  • Florit-Pons, Júlia
  • Coego, Sara
  • Prieto, Pilar
[eng] The MultiModal Imitation Task (MMIT) has been developed to jointly assess the imitation of sentence, prosody, and gestures in children. The MMIT focuses on multimodal language abilities and includes four scores (sentence imitation, prosody imitation, gesture imitation, MMIT total). Psychometric properties of the tool were analyzed on a sample of 235 typically developing children 3 to 6 years of age. The results showed good validity and reliability of the tool. The MMIT had excellent internal consistency and interrater reliability, suggesting that the items are coherent and intercorrelated and the scoring system is reliable. The MMIT showed adequate convergent validity with other previously validated and standardized tests to assess sentence and prosody imitation. The relevance and adequacy of the MMIT items were confirmed by expert evaluations. Overall, the MMIT is a valuable, reliable, appropriate, and practical tool for the assessment of multimodal imitation skills in children of preschool and primary school ages.
Repositori Obert UdL
Publicación Capítulo o parte de un libro (BookPart)

La atracción de los iguales. Sociedad, migraciones y alianzas matrimoniales en la Lleida del siglo XVI

  • Vilalta i Escobar, María José
Este trabajo ha sido financiado por el Ministerio de Educación y Ciencia, Plan Nacional 2003-2006, proyecto: Migraciones, redes sociales y mercado (siglos XVI-XVIII) (BHA, 2003-00778).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Interleukin-11 promotes lung adenocarcinoma tumourigenesis and immune evasion

  • Cirauqui, Cristina
  • Ojeda, Laura
  • Otano, Itziar
  • Pazos, Irene
  • Santos, Alba
  • Garrido-Martin, Eva M.
  • Yagüe, Patricia
  • Ramos-Paradas, Javier
  • Molina-Pinelo, Sonia
  • Roncador, Giovanna
  • Solórzano, José Luis
  • Muñoz Jiménez, María Teresa
  • Cozar, Patricia
  • Plaza, Patricia
  • Suárez, Rocío
  • Jiménez, Marta
  • Moreno, Roberto
  • Rosado, Arantxa
  • Gámez, Pablo
  • García-Luján, Ricardo
  • Zugazagoitia, Jon
  • Sweet-Cordero, Alejandro
  • Barbacid, Mariano
  • Carnero, Amancio
  • Ferrer, Irene
  • Paz-Ares, Luis
Cristina Cirauqui, Laura Ojeda, Irene Ferrer and Luis Paz-Ares contributed equally to this work., [Rationale] Interleukin-11 (IL-11) has emerged as a significant player in tumourigenesis, with implications across various cancer types. However, its specific role in driving tumour progression in lung adenocarcinoma (LUAD) remains elusive. IL-11's multifaceted impact on both tumour cells and the tumour microenvironment underscores its potential as a therapeutic target in LUAD. This study aims to unravel the involvement of IL-11 in LUAD progression and its influence on the tumour microenvironment., [Methods] Here, we used transcriptomic and digital spatial profiling analyses together with clinic data from two retrospective LUAD patient cohorts. LUAD cell lines genetically engineered to overexpress or to silence IL-11 or its receptor (IL-11RA) were used for in vitro functional analysis and for in vivo experiments. Additionally, we used three different in vivo models: patient-derived xenografts (PDXs), tobacco-exposed mice and genetically engineered mouse models. A neutralising monoclonal antibody against IL-11RA was produced and tested., [Results] Our findings revealed a pivotal role for IL-11 in driving tumourigenesis across various mouse models, highlighting its capacity to modulate tumour immunity towards an immunosuppressive microenvironment. Moreover, we observed a correlation between IL-11 expression and poorer patient outcomes in LUAD. Notably, therapeutic targeting of IL-11RA with a neutralising antibody demonstrated significant anti-tumour efficacy in a PDX model., [Conclusion] The IL-11/IL-11RA axis emerges as a critical driver of LUAD tumourigenesis, exerting its effects through enhanced tumour cell proliferation and remodelling of the tumour microenvironment. Our study highlights the therapeutic potential of disrupting this axis, suggesting that patients exhibiting elevated IL-11 levels may benefit from therapies targeting the IL-11/IL-11RA pathway., We would like to acknowledge patients and their families for donating tumour tissue. We would also like to thank Alicia Maroto Pérez and Carolina Castilla, as well as the Biobank of the Hospital 12 de Octubre and Hospital Virgen del Rocío for kindly providing the samples used in this study. Appreciation is also expressed to Ines Muñoz and Jorge L. Martinez-Torrecuadrada (CNIO) for producing the recombinant human IL-11 and IL-11RA. L.P.-A. was funded by CAM, (B2017/BMD3884, P2022/BMD-7437), Fundación CRIS contra el cancer, CIBERONC (CD16/12/00442) and ISCIII (PI17/00778; PI20/00870; AC20/0070) and I.F. by AECC (AIO2015) and ISCIII (PI16/01311; PI19/00320; CP21/00052) and co-funded by FEDER (European Union). L.O. is funded by the Spanish Ministry of Education (FPU13/02595) and C.C. by ISCIII (CD21/00165). AC was funded by grants from the Ministerio de Ciencia, Innovación y Universidades (MCIU), Plan Estatal de I+D+I 2021, Agencia Estatal de Investigación (AEI), Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): ID2021-122629OB-I00 and CIBER de Cáncer (CB16/12/00275). EASC was funded by U01CA199216 from the National Cancer Institute. S.M.-P. was funded by the Ministry of Health and Social Welfare of the Junta de Andalucía (Nicolas Monardes Program RC-0004-2020, and PECART-0091-2020), Andalusian Research, Development and Innovation Plan (PY20_00992) and ISCIII (PI20/01109) and co-funded by FEDER from Regional Development European Funds (European Union)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Capítulo o parte de un libro (BookPart)

La atracción de los iguales. Sociedad, migraciones y alianzas matrimoniales en la Lleida del siglo XVI

  • Vilalta i Escobar, María José
Este trabajo ha sido financiado por el Ministerio de Educación y Ciencia, Plan Nacional 2003-2006, proyecto: Migraciones, redes sociales y mercado (siglos XVI-XVIII) (BHA, 2003-00778).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Meeting equitable (health) needs, a call for radical reflexivity in implementing interventions for just health outcomes

  • O Neill, Ella|||0009-0008-2861-9629
  • Luger, Jonathan|||0000-0003-1669-7183
Urban interventions for health are widespread, yet doubts exist about their capacity to address residents' needs equitably. It is common for interventions to attempt some form of participation to include marginalised residents. Scholars emphasise the need for this to be meaningful. Nonetheless, despite the theorisation and subsequent recommendations on how participation should be carried out, it often continues to fall short in practice, as tokenistic or passive participation, with limited political impact. We reflect on a widely unexplored factor: how a lack of diversity in the decision-making teams of projects might shape participation. To do so, we reflect on our experiences working in health interventions teams, one in neighbourhood food environments in Amsterdam and the other in urban green spaces in London. Both projects had an explicit mandate to reach marginalised communities to address health inequities, using co-creation to achieve this. We unpack challenges brought by a lack of diversity in teams, identifying structural factors at play. We thus propose that a radical reflexivity in interventions should move beyond theory, to how participation unfolds in practice, and at least requires critically interrogating funding structures, hiring practices and team members' positionalities.